Table 2.
Risk factors for central nervous system infiltration among patients with diffuse large B-cell lymphoma in the Santa Casa cohort: univariate analysis
| Central nervous system outcome | Incidence | Rate of incidence | p-value | |
| Age (years) | ||||
| < 60 years | 2.9 | reference | 0.106 | |
| ≥ 60 years | 0.6 | 0.21 (0.03; 1.69) | ||
| Gender | ||||
| Female | 0.5 | reference | 0.034 | |
| Male | 3.4 | 6.91 (1.86-55.28) | ||
| Extranodal sites | ||||
| ≤ 1 | 1.9 | reference | 0.594 | |
| ≥ 2 | 3.4 | 1.75 (0.22-13.98) | ||
| Bulky disease* | ||||
| No | 1.7 | reference | 0.414 | |
| Yes | 3.1 | 1.75 (0.44-7.07) | ||
| Stage | ||||
| I/II | 0.8 | reference | 0.037 | |
| III/IV | 3.7 | 4.58 (1.95-22.03) | ||
| B symptoms** | ||||
| No | 1.0 | reference | 0.130 | |
| Yes | 3.0 | 3.15 (0.66-15.18) | ||
| International Prognostic Index | ||||
| 0-2 | 2.0 | reference | 0.888 | |
| 3-5 | 2.2 | 1.1 (0.28-4.42) | ||
| Bone marrow biopsy | ||||
| Negative | 2.1 | reference | 0.680 | |
| Positive | 3.2 | 1.54 (0.19-12.34) | ||
| Lactic dehydrogenase (g/dL) | ||||
| Normal | 0.9 | reference | 0.321 | |
| Elevated | 2.4 | 2.74 (0.34-21.93) | ||
| Hemoglobin (g/dL) | ||||
| ≥ 10.5 | 1.5 | reference | 0.027 | |
| < 10.5 | 6.4 | 4.2 (1.05-16.78) | ||
| Albumin (g/dL) | ||||
| ≥ 4 | 1.7 | reference | 0.919 | |
| < 4 | 1.5 | 0.92 (0.17-5.00) | ||
| Beta-2-microglobulin (mg/L) | ||||
| Normal | 1.4 | reference | 0.965 | |
| Increased | 1.4 | 0.95 (0.09-10.45) | ||
| Treatment | ||||
| Chemotherapy | 3.0 | 3.85 (0.48-30.82) | 0.170 | |
| Chemotherapy + radiotherapy | 0.8 | reference | ||
| Response | ||||
| Complete | 1.0 | reference | ||
| Partial | 1.8 | 1.79 (0.19-17.16) | 0.611 | |
| Refractory | 8.7 | 8.74 (2.09-36.57) | < 0.00100 | |
*
Bulky: mass size > 10 cm
**
B symptoms: night fever, night sweats and fever